RU2004114992A - Аддитивные цитопротекторные эффекты двух биоактивных областей гормона про-опиомеланокортина - Google Patents

Аддитивные цитопротекторные эффекты двух биоактивных областей гормона про-опиомеланокортина Download PDF

Info

Publication number
RU2004114992A
RU2004114992A RU2004114992/15A RU2004114992A RU2004114992A RU 2004114992 A RU2004114992 A RU 2004114992A RU 2004114992/15 A RU2004114992/15 A RU 2004114992/15A RU 2004114992 A RU2004114992 A RU 2004114992A RU 2004114992 A RU2004114992 A RU 2004114992A
Authority
RU
Russia
Prior art keywords
pro
opiomelanocortin
bioactive
drugs
cytoprotective effects
Prior art date
Application number
RU2004114992/15A
Other languages
English (en)
Other versions
RU2297238C2 (ru
Inventor
Златко АДЕМОВИЧ (BA)
Златко АДЕМОВИЧ
Никола ШТАМБУК (HR)
Никола ШТАМБУК
Паско КОНЬЕВОДА (HR)
Паско КОНЬЕВОДА
Дарко МИКУШ (HR)
Дарко МИКУШ
Original Assignee
Златко АДЕМОВИЧ (BA)
Златко АДЕМОВИЧ
Никола ШТАМБУК (HR)
Никола ШТАМБУК
Паско КОНЬЕВОДА (HR)
Паско КОНЬЕВОДА
Дарко МИКУШ (HR)
Дарко МИКУШ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Златко АДЕМОВИЧ (BA), Златко АДЕМОВИЧ, Никола ШТАМБУК (HR), Никола ШТАМБУК, Паско КОНЬЕВОДА (HR), Паско КОНЬЕВОДА, Дарко МИКУШ (HR), Дарко МИКУШ filed Critical Златко АДЕМОВИЧ (BA)
Publication of RU2004114992A publication Critical patent/RU2004114992A/ru
Application granted granted Critical
Publication of RU2297238C2 publication Critical patent/RU2297238C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (4)

1. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET, характеризующихся структурными формулами SYSMEHFRWGKPV и YGGFM (таблица 1), для синтеза лекарств, которые используются как системные и местные препараты.
2. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET-1, характеризующихся структурной формулой YGGFMSYSMEHFRWGKPVYGGFM, для синтеза лекарств, которые используются как системные и местные препараты.
3. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET-2, характеризующихся структурными формулами YGGFMSYSMEHFRWGKPV, для синтеза лекарств, которые используются как системные и местные препараты.
4. Комбинация двух биоактивных и повторяющихся последовательностей про-опиомеланокортина KOMET-3, характеризующихся структурными формулами SYSMEHFRWGKPVYGGFM, для синтеза лекарств, которые используются как системные и местные препараты.
RU2004114992/15A 2001-10-18 2001-11-29 Аддитивные цитопротекторные эффекты двух биоактивных областей гормона про-опиомеланокортина RU2297238C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BABAP01898A 2001-10-18
BA010898 2001-10-18

Publications (2)

Publication Number Publication Date
RU2004114992A true RU2004114992A (ru) 2005-04-20
RU2297238C2 RU2297238C2 (ru) 2007-04-20

Family

ID=3839672

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004114992/15A RU2297238C2 (ru) 2001-10-18 2001-11-29 Аддитивные цитопротекторные эффекты двух биоактивных областей гормона про-опиомеланокортина

Country Status (15)

Country Link
US (1) US7544653B2 (ru)
EP (1) EP1435999B1 (ru)
JP (1) JP2005508356A (ru)
CN (1) CN1321687C (ru)
AU (1) AU2002240733B2 (ru)
BR (1) BR0117155A (ru)
CA (1) CA2462713C (ru)
CY (1) CY1114016T1 (ru)
DK (1) DK1435999T3 (ru)
ES (1) ES2391551T3 (ru)
MX (1) MXPA04003504A (ru)
NO (1) NO20042001L (ru)
PT (1) PT1435999E (ru)
RU (1) RU2297238C2 (ru)
WO (1) WO2003033017A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2857588B1 (fr) * 2003-07-17 2007-11-30 Oreal Utilisation de beta-endorphine, d'agents exercant une activite beta-endorphine-like en cosmetique et dermatologie
AU2011265315B2 (en) * 2004-05-12 2014-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
WO2010054446A1 (en) 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
WO2015033175A1 (en) 2013-09-06 2015-03-12 Zlatko Ademovic Combination of pro-opiomelanocortin endogenous peptides in autoimmune disease treatment
US10644009B2 (en) 2017-12-21 2020-05-05 Renesas Electronics Corporation Semiconductor memory device
CN109824772B (zh) * 2019-02-28 2022-07-29 海南大学 一组提高血清糖皮质激素水平的基因重组人促皮质素前体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836386T2 (de) * 1997-08-22 2007-10-11 Kaken Pharmaceutical Co., Ltd. Amide zur Förderung der Ausschüttung von Wachstumshormonen
AU5055799A (en) * 1998-07-22 2000-02-14 Smith & Nephew Plc Dermatological compositions for the treatment of scars
DE60026300T2 (de) * 1999-05-17 2006-11-16 Conjuchem, Inc., Montreal Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile

Also Published As

Publication number Publication date
JP2005508356A (ja) 2005-03-31
PT1435999E (pt) 2012-10-24
AU2002240733B2 (en) 2009-04-09
CN1321687C (zh) 2007-06-20
BR0117155A (pt) 2004-10-26
CA2462713C (en) 2014-03-18
ES2391551T3 (es) 2012-11-27
EP1435999B1 (en) 2012-07-18
CY1114016T1 (el) 2016-07-27
MXPA04003504A (es) 2005-06-20
US7544653B2 (en) 2009-06-09
WO2003033017A1 (en) 2003-04-24
EP1435999A1 (en) 2004-07-14
US20050014696A1 (en) 2005-01-20
NO20042001L (no) 2004-05-14
DK1435999T3 (da) 2012-10-22
CA2462713A1 (en) 2003-04-24
CN1558772A (zh) 2004-12-29
RU2297238C2 (ru) 2007-04-20

Similar Documents

Publication Publication Date Title
IS6658A (is) Ný efnasambönd
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
HK1048990A1 (en) Novel compounds.
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
SE0300119D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
SE0302139D0 (sv) Novel compounds
ATE291021T1 (de) Oxytocin agonisten
ATE300541T1 (de) Pyrazolopyridinderivate
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
SE0101038D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds
RU2004114992A (ru) Аддитивные цитопротекторные эффекты двух биоактивных областей гормона про-опиомеланокортина
IL151198A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
SE9903290D0 (sv) Novel compounds
ATE274515T1 (de) Pyrazolopyridinderivate
SE9904128D0 (sv) Novel compounds
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
ATE364619T1 (de) Tibolonformulierungen

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20141208

QB4A Licence on use of patent

Free format text: LICENCE

Effective date: 20151102

PC41 Official registration of the transfer of exclusive right

Effective date: 20190708